BUZZ-UBS initiates Indian pharma coverage amid weight-loss drug opportunity

Reuters03-25

BUZZ-UBS initiates Indian pharma coverage amid weight-loss drug opportunity

** UBS starts coverage of Indian pharmaceutical sector; says sector faces limited impact from Middle Eastern war given resilient demand, inventory buffers and strong balance sheets

** Brokerage says it expects generic semaglutide to be subject to intense pricing pressure driven by aggressive generic launches

** UBS estimates generic GLP-1 market opportunity to reach $7.6 billion by 2030 for Indian pharma companies and says Sun Pharma SUN.NS is best placed to capture this long-term opportunity

** Assumes coverage of SUN with "buy" rating, tags it preferred pick in the sector, as co well-positioned with innovative medicines and a robust pipeline to support earnings

** UBS assigns "neutral" to Cipla CIPL.NS and Aurobindo Pharma ARBN.NS and "sell" to Dr. Reddy's REDY.NS, Lupin LUPN.NS and Zydus Life ZYDU.NS

** Pharma index .NIPHARM up 1.8%, with SUN, CIPL rising 1.6% each and ARBN gaining 2.8%; REDY, LUPIN and ZYDU are up between 0.6% and 2.8%

(Reporting by Bharath Rajeswaran in Bengaluru)

((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622044985?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 13:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622044985","market":"us","top_or_hot":-1,"title":"BUZZ-UBS initiates Indian pharma coverage amid weight-loss drug opportunity","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-UBS initiates Indian pharma coverage amid weight-loss drug opportunity</title></head><body><p>** UBS starts coverage of Indian pharmaceutical sector; says sector faces limited impact from Middle Eastern war given resilient demand, inventory buffers and strong balance sheets</p><p>** Brokerage says it expects generic semaglutide to be subject to intense pricing pressure driven by aggressive generic launches  </p><p>** UBS estimates generic GLP-1 market opportunity to reach $7.6 billion by 2030 for Indian pharma companies and says Sun Pharma <span>SUN.NS</span> is best placed to capture this long-term opportunity</p><p>** Assumes coverage of SUN with \"buy\" rating, tags it preferred pick in the sector, as co well-positioned with innovative medicines and a robust pipeline to support earnings</p><p>** UBS assigns \"neutral\" to Cipla <span>CIPL.NS</span> and Aurobindo Pharma <span>ARBN.NS</span> and \"sell\" to Dr. Reddy's <span>REDY.NS</span>, Lupin <span>LUPN.NS</span> and Zydus Life <span>ZYDU.NS</span></p><p>** Pharma index <span>.NIPHARM</span> up 1.8%, with SUN, CIPL rising 1.6% each and ARBN gaining 2.8%; REDY, LUPIN and ZYDU are up between 0.6% and 2.8%</p><p> (Reporting by Bharath Rajeswaran in Bengaluru)</p><p> ((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-UBS initiates Indian pharma coverage amid weight-loss drug opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-UBS initiates Indian pharma coverage amid weight-loss drug opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-25 13:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-UBS initiates Indian pharma coverage amid weight-loss drug opportunity</title></head><body><p>** UBS starts coverage of Indian pharmaceutical sector; says sector faces limited impact from Middle Eastern war given resilient demand, inventory buffers and strong balance sheets</p><p>** Brokerage says it expects generic semaglutide to be subject to intense pricing pressure driven by aggressive generic launches  </p><p>** UBS estimates generic GLP-1 market opportunity to reach $7.6 billion by 2030 for Indian pharma companies and says Sun Pharma <span>SUN.NS</span> is best placed to capture this long-term opportunity</p><p>** Assumes coverage of SUN with \"buy\" rating, tags it preferred pick in the sector, as co well-positioned with innovative medicines and a robust pipeline to support earnings</p><p>** UBS assigns \"neutral\" to Cipla <span>CIPL.NS</span> and Aurobindo Pharma <span>ARBN.NS</span> and \"sell\" to Dr. Reddy's <span>REDY.NS</span>, Lupin <span>LUPN.NS</span> and Zydus Life <span>ZYDU.NS</span></p><p>** Pharma index <span>.NIPHARM</span> up 1.8%, with SUN, CIPL rising 1.6% each and ARBN gaining 2.8%; REDY, LUPIN and ZYDU are up between 0.6% and 2.8%</p><p> (Reporting by Bharath Rajeswaran in Bengaluru)</p><p> ((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0046","symbol_name":"生物疫苗","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4N40D0GA:1","article_id":"2622044985","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622044985","pubTimestamp":1774417642,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-UBS initiates Indian pharma coverage amid weight-loss drug opportunity** UBS starts coverage of Indian pharmaceutical sector; says sector faces limited impact from Middle Eastern war given resilient demand, inventory buffers and strong balance sheets** Brokerage says it expects generic semaglutide to be subject to intense pricing pressure driven by aggressive generic launches  ** UBS estimates generic GLP-1 market opportunity to reach $7.6 billion by 2030 for Indian pharma companies and says Sun Pharma SUN.NS is best placed to capture this long-term opportunity** Assumes coverage of SUN with \"buy\" rating, tags it preferred pick in the sector, as co well-positioned with innovative medicines and a robust pipeline to support earnings** UBS assigns \"neutral\" to Cipla CIPL.NS and Aurobindo Pharma ARBN.NS and \"sell\" to Dr. Reddy's REDY.NS, Lupin LUPN.NS and Zydus Life ZYDU.NS** Pharma index .NIPHARM up 1.8%, with SUN, CIPL rising 1.6% each and ARBN gaining 2.8%; REDY, LUPIN and ZYDU are","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300485":"赛升药业","BK0046":"生物疫苗","BK0239":"医药制造","BK0028":"国家队","BK0012":"证金概念"},"translate_title":"BUZZ-UBS在减肥药机会中启动印度制药业务","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300485":0.9},"content_text":"BUZZ-UBS initiates Indian pharma coverage amid weight-loss drug opportunity** UBS starts coverage of Indian pharmaceutical sector; says sector faces limited impact from Middle Eastern war given resilient demand, inventory buffers and strong balance sheets** Brokerage says it expects generic semaglutide to be subject to intense pricing pressure driven by aggressive generic launches  ** UBS estimates generic GLP-1 market opportunity to reach $7.6 billion by 2030 for Indian pharma companies and says Sun Pharma SUN.NS is best placed to capture this long-term opportunity** Assumes coverage of SUN with \"buy\" rating, tags it preferred pick in the sector, as co well-positioned with innovative medicines and a robust pipeline to support earnings** UBS assigns \"neutral\" to Cipla CIPL.NS and Aurobindo Pharma ARBN.NS and \"sell\" to Dr. Reddy's REDY.NS, Lupin LUPN.NS and Zydus Life ZYDU.NS** Pharma index .NIPHARM up 1.8%, with SUN, CIPL rising 1.6% each and ARBN gaining 2.8%; REDY, LUPIN and ZYDU are up between 0.6% and 2.8% (Reporting by Bharath Rajeswaran in Bengaluru) ((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622044985","isCrawlerRequest":true}